Dabigatran (Pradaxa)


Systemic Embolism Prevention in Nonvalvular Atrial Fibrillation (see Atrial Fibrillation, [[Atrial Fibrillation]])

Venous Thromboembolism-Deep Venous Thrombosis (DVT)/Acute Pulmonary Embolism (PE) (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]] and Acute Pulmonary Embolism, [[Acute Pulmonary Embolism]])

Venous Thromboembolism Prophylaxis Post-Knee and Hip Replacement (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]])




Drug Interactions


PO Dosing

Hepatic Dose-Adjustment

Renal Dose-Adjustment

Venous Thromboembolism

Non-Valvular Atrial Fibrillation

Venous Thromboembolism Prophylaxis

Effect on Anticoagulation Tests

Conversion from/to Other Anticoagulants

Conversion from Dabigatran

Conversion to Dabigatran

Abrupt Discontinuation of Dabigatran

Management of Dabigatran Anticoagulation for Procedures

Reversal of Anticoagulation

Adverse Effects

Hemorrhagic Adverse Effects

General Comments

Post-Hip Replacement or Knee Replacement DVT Prophylaxis Trials

Atrial Fibrillation Trials

Venous Thrombembolism Trials

Comparative Rates of Hemorrhage Between Coumadin and Novel Oral Anticoagulants

Types of Hemorrhage

Other Adverse Effects